These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35000792)

  • 21. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
    Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report.
    Sansone VA; Walter MC; Attarian S; Delstanche S; Mercuri E; Lochmüller H; Neuwirth C; Vazquez-Costa JF; Kleinschnitz C; Hagenacker T
    J Neuromuscul Dis; 2020; 7(4):523-534. PubMed ID: 32538864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy.
    Maharshi V; Hasan S
    Clin Drug Investig; 2017 Sep; 37(9):807-817. PubMed ID: 28755059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1.
    Verrillo E; Pavone M; Bruni O; Ferri R; Chiarini Testa MB; Cherchi C; D'Amico A; Cutrera R
    Sleep Med; 2023 Oct; 110():106-110. PubMed ID: 37572575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
    Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
    BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
    Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
    J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
    Crawford TO; Darras BT; Day JW; Dunaway Young S; Duong T; Nelson LL; Barrett D; Song G; Bilic S; Cote S; Sadanowicz M; Iarrobino R; Xu TJ; O'Neil J; Rossello J; Place A; Kertesz N; Nomikos G; Chyung Y
    Neurology; 2024 Mar; 102(5):e209151. PubMed ID: 38330285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
    Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
    J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
    Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
    Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
    Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
    Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
    Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
    Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
    Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.